Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
about
Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infectionActivation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.Telomerase activity impacts on Epstein-Barr virus infection of AGS cells.TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphismLatent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infectionDistinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin.Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells.Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells.Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production.
P2860
Q27022706-B1657264-7CA7-4255-8F61-6049EF030A8FQ34059398-A49EF7D8-A4FD-405D-96DC-E4491D74E132Q35598260-4C855FDB-582A-4EF2-8B5A-36A35B130892Q36071989-7B59E8B5-B2CE-4D1A-81E2-D68AE5DF6A69Q36483287-D4401E9D-188B-4E38-B10B-DA97CA630B84Q36540111-DED1E7A0-B6B1-4731-B0E1-5D648B58431EQ37074285-ACE133B4-E12C-4791-9668-4CB7D54DDA32Q37456672-E5E7BFC2-A66D-48BA-B214-0BFD08537F2AQ37673449-3ADB7C74-C02C-44F6-88F9-23EF8DF4ED13Q39609877-CBE31734-3F2D-4036-983E-070B1E497A86Q42264347-28AE6FB2-DD5A-4F6E-A9D5-34653E5A6848Q44267868-F54C5EED-3B88-4814-933C-6780D6FB3A24Q51888725-DA4F67F2-AE45-4C25-9FA9-C3B8A37D40B3
P2860
Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
@en
type
label
Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
@en
prefLabel
Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
@en
P2093
P2860
P50
P1476
Immune activation suppresses initiation of lytic Epstein-Barr virus infection
@en
P2093
Christoph Berger
David Nadal
Franziska Zucol
Ludwig Zauner
P2860
P304
P356
10.1111/J.1462-5822.2007.00937.X
P577
2007-04-05T00:00:00Z